{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:03:51Z","timestamp":1792213431189,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43606-5","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:55:31Z","timestamp":1773244531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8775-2840","authenticated-orcid":false,"given":"Arturo","family":"Llobell-Uriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Gonz\u00e1lez-Maz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Gratac\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Retamozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Secada-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Mart\u00edn-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Garc\u00eda-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fern\u00e1ndez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gallardo-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Berenguer-Llergo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"del Estal-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Delgado-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"G\u00f3mez-Centeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Segui-Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"4","key":"43606_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 27 (4), 450\u2013461 (2015).","journal-title":"Cancer Cell."},{"key":"43606_CR2","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui, R., Zhou, L. & He, S. Cancer immunotherapies: advances and bottlenecks. Front. Immunol. 14, 1212476 (2023).","journal-title":"Front. Immunol."},{"issue":"4","key":"43606_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","volume":"5","author":"KPM Suijkerbuijk","year":"2024","unstructured":"Suijkerbuijk, K. P. M., van Eijs, M. J. M., van Wijk, F. & Eggermont, A. M. M. Clinical and translational attributes of immune-related adverse events. Nat. Cancer. 5 (4), 557\u2013571 (2024).","journal-title":"Nat. Cancer"},{"issue":"9","key":"43606_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management, and surveillance. Nat. Rev. Clin. Oncol. 16 (9), 563\u2013580 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"43606_CR5","doi-asserted-by":"publisher","first-page":"e008876","DOI":"10.1136\/jitc-2024-008876","volume":"13","author":"A Cesano","year":"2025","unstructured":"Cesano, A. et al. Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review. J. Immunother Cancer. 13 (1), e008876 (2025).","journal-title":"J. Immunother Cancer"},{"issue":"3","key":"43606_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/BOR.0000000000000935","volume":"35","author":"M Defoe","year":"2023","unstructured":"Defoe, M. & Bermas, B. L. Rheumatologic immune checkpoint inhibitor-related adverse events. Curr. Opin. Rheumatol. 35 (3), 141\u2013148 (2023).","journal-title":"Curr. Opin. Rheumatol."},{"issue":"3","key":"43606_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","volume":"145","author":"P Arnaud-Coffin","year":"2019","unstructured":"Arnaud-Coffin, P. et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int. J. Cancer. 145 (3), 639\u2013648 (2019).","journal-title":"Int. J. Cancer"},{"key":"43606_CR8","doi-asserted-by":"publisher","first-page":"804597","DOI":"10.3389\/fimmu.2022.804597","volume":"13","author":"R Poto","year":"2022","unstructured":"Poto, R. et al. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front. Immunol. 13, 804597 (2022).","journal-title":"Front. Immunol."},{"key":"43606_CR9","doi-asserted-by":"publisher","first-page":"1447021","DOI":"10.3389\/fimmu.2024.1447021","volume":"15","author":"S Keam","year":"2024","unstructured":"Keam, S. et al. Toxicity in the era of immune checkpoint inhibitor therapy. Front. Immunol. 15, 1447021 (2024).","journal-title":"Front. Immunol."},{"issue":"Suppl 7","key":"43606_CR10","doi-asserted-by":"publisher","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","volume":"58","author":"M Kostine","year":"2019","unstructured":"Kostine, M., Truchetet, M. E. & Schaeverbeke, T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatol. (Oxford). 58 (Suppl 7), vii68\u2013vii74 (2019).","journal-title":"Rheumatol. (Oxford)"},{"issue":"11","key":"43606_CR11","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli, L. C., Gutierrez, A. K., Bingham, C. O. 3rd & Shah, A. A. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res. (Hoboken). 69 (11), 1751\u20131763 (2017).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"17","key":"43606_CR12","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 36 (17), 1714\u20131768 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"43606_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother Cancer. 5 (1), 95 (2017).","journal-title":"J. Immunother Cancer"},{"issue":"Suppl 7","key":"43606_CR14","doi-asserted-by":"publisher","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","volume":"58","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab, N. & Suarez-Almazor, M. E. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatol. (Oxford). 58 (Suppl 7), vii40\u2013vii48 (2019).","journal-title":"Rheumatol. (Oxford)"},{"issue":"1","key":"43606_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","volume":"41","author":"F Angelopoulou","year":"2021","unstructured":"Angelopoulou, F., Bogdanos, D., Dimitroulas, T., Sakkas, L. & Daoussis, D. Immune checkpoint inhibitor-induced musculoskeletal manifestations. Rheumatol. Int. 41 (1), 33\u201342 (2021).","journal-title":"Rheumatol. Int."},{"key":"43606_CR16","doi-asserted-by":"publisher","first-page":"152110","DOI":"10.1016\/j.semarthrit.2022.152110","volume":"58","author":"N Ghosh","year":"2023","unstructured":"Ghosh, N. et al. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group. Semin Arthritis Rheum. 58, 152110 (2023).","journal-title":"Semin Arthritis Rheum."},{"issue":"6","key":"43606_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/annrheumdis-2018-214748","volume":"78","author":"M Kostine","year":"2019","unstructured":"Kostine, M. et al. Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann. Rheum. Dis. 78 (6), 860\u2013862 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"43606_CR18","doi-asserted-by":"crossref","unstructured":"Ara\u00fajo, F. & Fonseca, J. A. B. Physician awareness of rheumatic immune-related adverse events in cancer patients treated with immune checkpoint inhibitorsAnnals of the Rheumatic Diseases 2018;77:1777\u20131778. (1386).","DOI":"10.1136\/annrheumdis-2018-eular.3831"},{"key":"43606_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","volume":"82","author":"S Le Burel","year":"2017","unstructured":"Le Burel, S. et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur. J. Cancer. 82, 34\u201344 (2017).","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"43606_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine, M. et al. FHU ACRONIM. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann. Rheum. Dis. 77 (3), 393\u2013398 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"43606_CR21","doi-asserted-by":"publisher","first-page":"803410","DOI":"10.3389\/fimmu.2021.803410","volume":"12","author":"N Hamada","year":"2021","unstructured":"Hamada, N. et al. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis. Front. Immunol. 12, 803410 (2021).","journal-title":"Front. Immunol."},{"key":"43606_CR22","doi-asserted-by":"publisher","first-page":"114148","DOI":"10.1016\/j.ejca.2024.114148","volume":"207","author":"MA Lopez-Olivo","year":"2024","unstructured":"Lopez-Olivo, M. A. et al. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and preexisting autoimmune disease. Eur. J. Cancer. 207, 114148 (2024).","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"43606_CR23","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand, Y. et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr. Oncol. 29 (5), 3044\u20133060 (2022).","journal-title":"Curr. Oncol."},{"issue":"7","key":"43606_CR24","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1007\/s00432-022-04309-2","volume":"149","author":"MN Wahli","year":"2023","unstructured":"Wahli, M. N. et al. The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex. J. Cancer Res. Clin. Oncol. 149 (7), 3847\u20133858 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"43606_CR25","doi-asserted-by":"publisher","first-page":"1759720X2110069","DOI":"10.1177\/1759720X211006963","volume":"13","author":"SH Verspohl","year":"2021","unstructured":"Verspohl, S. H., Holderried, T., Behning, C., Brossart, P. & Sch\u00e4fer, V. S. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Ther. Adv. Musculoskelet. Dis. 13, 1759720X211006963 (2021).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"3","key":"43606_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/ajco.13346","volume":"17","author":"H Zhong","year":"2021","unstructured":"Zhong, H., Zhou, J., Xu, D. & Zeng, X. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. Asia Pac. J. Clin. Oncol. 17 (3), 178\u2013185 (2021).","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"8","key":"43606_CR27","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.21037\/jtd-23-85","volume":"15","author":"R Onodera","year":"2023","unstructured":"Onodera, R. et al. High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study. J. Thorac. Dis. 15 (8), 4237\u20134247 (2023).","journal-title":"J. Thorac. Dis."},{"issue":"2","key":"43606_CR28","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","volume":"28","author":"N Ghosh","year":"2022","unstructured":"Ghosh, N., Chan, K. K., Jivanelli, B. & Bass, A. R. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review. J. Clin. Rheumatol. 28 (2), e498\u2013e505 (2022).","journal-title":"J. Clin. Rheumatol."},{"issue":"12","key":"43606_CR29","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33 (12), 1217\u20131238 (2022).","journal-title":"Ann. Oncol."},{"issue":"6","key":"43606_CR30","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother Cancer. 9 (6), e002435 (2021).","journal-title":"J. Immunother Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43606-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43606-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43606-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:26:16Z","timestamp":1776896776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43606-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43606"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43606-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7809077\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13159"}}